Loading...
By Kristin J. Kelley
Edited by William E. Chavey, MD, MS
The FDA has just given the go-ahead for the genetics testing company 23andMe to market the first direct-to-consumer tests that assess a person's predisposition to develop celiac disease, late-onset Alzheimer disease, Parkinson disease, and other conditions.
The Personal Genome Service Genetic Health Risk tests isolate DNA from a saliva sample and look for some 500,000 genetic variants, the absence or presence of which may indicate a predisposition for developing any one of 10 conditions or diseases. (See the linked news release for the full list.)
The tests only provide information, the FDA notes — environmental, lifestyle, and other factors also contribute to the development of a health condition. A study found that people who used the tests comprehended over 90% of the data in the reports.
Comment
LINK(S):
FDA news release (Free)
Background: Physician's First Watch coverage of 23andMe (Free)